This course analyzes the legal and policy regimes that shape the introduction of new products, processes, and services in the life science industries. Innovation in biopharmaceuticals, medical devices, health services, and health care delivery is central to the heavily regulated life sciences sector, and thus the sector offers a window into multiple intersections of scientific innovation, regulatory policy, and law. Innovation in this sector is also shaped by multiple bodies of law (e.g. intellectual property law, FDA law, federal and state-based insurance and professional regulation, antitrust, tax), each with its own private and public constituencies, and therefore offers an opportunity to assess how different bodies of law approach the common issue of innovation. Although this course focuses on innovation in the life science industries, this focus will produce lessons for innovation policy in other regulated and less-regulated industries.
Emerging tools for more equitable policy
» Professor Matthew Adler co-edited the new Oxford Handbook of Well-Being and Public Policy.
Prof. Sam Buell discusses his new book on the rise of criminal behavior in corporations and why it’s so difficult to prosecute.
The Duke way
» Public service is a core value of the legal profession and central to the Duke Law experience.
The Law and Policy of Innovation: the Life Sciences
*Please note that this information is for planning purposes only, and should not be relied upon for the schedule for a given semester. Faculty leaves and sabbaticals, as well as other curriculum considerations, will sometimes affect when a course may be offered.